Moll Wendén advises Scandinavian ChemoTech AB in an issue of shares amounting to approximately SEK 14.85 million with preferential rights for existing shareholders.
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech’s shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm.
Moll Wendén’s team has mainly consisted of Henric Stråth (responsible partner), Alexander Blom Vigsø and Eira Sjösvärd.